PrEP Adherence Decreases Over Time in Adolescent MSM

This article originally appeared here.
Share this content:
PrEP Adherence Decreases Over Time in Adolescent MSM
PrEP Adherence Decreases Over Time in Adolescent MSM

TUESDAY, Sept. 5, 2017 (HealthDay News) -- For adolescent men who have sex with men (MSM) participating in a 48-week HIV pre-exposure prophylaxis (PrEP) intervention, adherence decreases with quarterly visits, according to a study published online Sept. 5 in JAMA Pediatrics.

Sybil G. Hosek, Ph.D., from Stronger Hospital of Cook County in Chicago, and colleagues examined the safety of and adherence to PrEP and changes in sexual risk behavior among adolescent MSM. Participants were recruited from adolescent medicine clinics and their community partners; they completed an individualized evidence-based behavioral intervention and were provided with daily tenofovir disoproxil fumarate/emtricitabine for 48 weeks. Seventy-eight adolescents (mean age, 16.5 years) were enrolled (two Asian/Pacific Islanders, 23 blacks/African-Americans, 11 whites, 16 white Hispanics, and 26 participants of other/mixed race/ethnicity).

The researchers diagnosed 23 sexually transmitted infections in 12 participants over 48 weeks of PrEP use. Per 100 person-years, the HIV seroconversion rate was 6.4. At weeks four, eight, 12, 24, 36, and 48, tenofovir diphosphate levels consistent with a high degree of anti-HIV protection were found in 54, 47, 49, 28, 17, and 22 percent of participants, respectively.

"Approximately half achieved protective drug levels during the monthly visits, but adherence decreased with quarterly visits," the authors write. "Youth may need additional contact with clinical staff members to maintain high adherence."

Two authors disclosed ties to pharmaceutical companies, including Gilead Sciences, which provided funding and drugs for the study.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »